Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.
Voluntarily understand and sign the informed consent form for this study.
Age ≥ 18 years, male or female.
Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition).
ECOG performance status of 0-2.
Inability to comply with the study protocol or study procedures.
Presence of supraclavicular lymph node metastasis.
Obvious tumor invasion of organs adjacent to the esophageal lesion.
Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment.
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor